Respiratory Disease Stratification Using Blood Biomarker Spectroscopy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The challenge in differentiating between viral and bacterial pneumonia, particularly during the COVID-19 pandemic, is exacerbated by similar symptoms, leading to difficulties in early diagnosis and timely treatment, especially in severe cases requiring ICU admission.
Innovation Solution
A method involving a fluid sample from a patient, where a light signal is used to acquire a spectrogram, extracting features that are compared to a model to determine the severity of respiratory disease, incorporating demographic features for improved accuracy, utilizing a device with a laser and optical fiber for illumination and data acquisition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If diagnosis is based on clinical features and chest radiography, then the diagnostic process is simple and accessible, but the ability to differentiate between viral and bacterial pneumonia is insufficient
Solution Approach 1:
The patent introduces blood biomarkers (procalcitonin, C-reactive protein, interleukin-6) as intermediary substances that mediate the differentiation between viral and bacterial pneumonia. These biomarkers serve as objective indicators that complement clinical features and imaging, enabling more precise diagnosis without requiring complex diagnostic equipment or procedures.
Solution Approach 2:
The patent utilizes changes in biochemical parameters (concentration levels of procalcitonin, C-reactive protein, interleukin-6) to differentiate between types of pneumonia. By monitoring these parameter changes in blood samples, the system achieves improved diagnostic precision while maintaining simplicity, as blood tests are already a standard, accessible diagnostic tool.
2Measurement precision
If microbiological data from blood culture or sputum culture is obtained, then the identification of causative microorganism is improved, but the time required for diagnosis increases
Solution Approach 1:
The patent employs preliminary diagnostic actions by measuring blood biomarkers (procalcitonin, C-reactive protein, interleukin-6) that can be detected quickly without requiring time-consuming culture procedures. These biomarkers provide early indicators of bacterial infection, enabling rapid diagnosis and timely initiation of antibiotic therapy before culture results are available.
Solution Approach 2:
The patent replaces the mechanical/time-consuming process of bacterial culture identification with a biochemical measurement approach. Instead of waiting for microorganisms to grow and be identified through culture, the system uses rapid detection of inflammatory biomarkers in blood, significantly reducing diagnosis time while maintaining identification accuracy.
3Measurement precision
If chest CT scan is performed to confirm suspected COVID-19, then the diagnostic accuracy is improved, but the accessibility and availability of the test decreases
Solution Approach 1:
The patent introduces blood biomarkers as intermediary diagnostic tools that mediate between clinical suspicion and confirmed diagnosis. These biomarkers can be measured using standard laboratory techniques that are more accessible than CT scanning, particularly in resource-limited settings. The biomarkers provide sufficient diagnostic accuracy to guide management decisions without requiring advanced imaging infrastructure.
4Reliability
If mechanical ventilation is used to support breathing in severe cases, then the patient survival chance is improved, but the probability of acquiring hospital acquired infections increases
Solution Approach 1:
The patent enables preliminary detection of bacterial co-infections through rapid measurement of blood biomarkers (procalcitonin, C-reactive protein, interleukin-6) before hospital acquired infections develop. This allows for early initiation of targeted antibiotic therapy, preventing the development of severe infections in mechanically ventilated patients and reducing the need for aggressive infection control measures.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables quick analysis and stratification of respiratory disease severity, enhancing triage and treatment decisions by accurately distinguishing between severe and non-severe cases, thereby improving patient outcomes.
Implementation Method 1
producing a light signal from a laser and illuminating the fluid sample with the light signal through a lens in a sensing probe
Data Source
AI summary
A method for stratifying a patient infected with a respiratory disease is disclosed. The method comprises providing (1510) a fluid sample (9) from the patient, producing (1520) a light signal from a laser (1), illuminating (1530) the fluid sample (9) with the light signal through a lens in a sensing probe (8), acquiring (1540) a spectrogram from the fluid sample (9), extracting (1550) a plurality of spectrogram features from the light signal, comparing (1560) the extracted plurality of spectrogram features with a model in a database to determine a degree of severity of the respiratory disease. A result is then output (1570) to indicate the degree of severity of the respiratory disease.